The transaction
What happened
The second close expanded the seed round from an initial €11.5m to €17m. Biovance's €4m investment is one investor's contribution, not the whole round.
Funding supports oncology and immunology research. The investor's announcement also sets out plans for Laigo to expand activities and recruit in Portugal; it does not establish completed expansion or clinical outcomes.
What to watch
The announced Portuguese activity and later research or financing milestones, each verified separately.